Only in Titles

           Search results for: KinaseSTAR JNK Activity Screening Kit   

paperclip

#28843994   2017/08/27 Save this To Up

NRG-1β exerts neuroprotective effects against ischemia reperfusion-induced injury in rats through the JNK signaling pathway.

Neuregulin-1β (NRG-1β) has great potential to be developed into therapeutics for neuroprotection. The aim of the current study was to analyze the effects and possible signaling pathway of NRG-1β on brain tissues in a rat model of middle cerebral artery occlusion/reperfusion (MCAO/R).

2043 related Products with: NRG-1β exerts neuroprotective effects against ischemia reperfusion-induced injury in rats through the JNK signaling pathway.

AP-1 Reporter – HEK293 AKT PKB Signaling Phospho AMPK Signaling Phospho-Sp ErbB Her Signaling Phosph ERK Signaling Phospho-Spe GPCR Signaling to MAPK ER IGF-1R Signaling Phospho- NF-kB II Phospho-Specific p53 Signaling Phospho-Spe T-Cell Receptor Signaling TGF-Beta Signaling Phosph DiscoveryPak™ Hedgehog

Related Pathways

paperclip

#26362062   2015/09/12 Save this To Up

Activation of SAPK/JNK mediated the inhibition and reciprocal interaction of DNA methyltransferase 1 and EZH2 by ursolic acid in human lung cancer cells.

Ursolic acid (UA), a pentacyclic triterpenoid, is known to have anti-tumor activity in various cancers including human non small cell lung cancer (NSCLC). However, the molecular mechanisms underlying the action of UA remain largely unknown.

1002 related Products with: Activation of SAPK/JNK mediated the inhibition and reciprocal interaction of DNA methyltransferase 1 and EZH2 by ursolic acid in human lung cancer cells.

Goat Anti-Human DNA Methy Rabbit Anti-Human Androge Macrophage Colony Stimula GSK-126 Mechanisms: EZH2 Androst-4-ene-3,17-dion-1 Lung cancer tissue array AccuPrep Genomic DNA Extr Lung non small cell cance Lung cancer tissue array, Lung cancer survey tissue Lung cancer survey tissue High density Lung cancer

Related Pathways

paperclip

#18060025   2007/12/06 Save this To Up

Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.

Imatinib, a selective, small-molecule tyrosine kinase inhibitor, has life-saving clinical activity in certain cancers, but questions have been raised about the potential for cardiac toxicity through inhibition of its target, ABL kinase. In this issue of the JCI, Fernández et al. describe a novel method by which the ABL-inhibitory activity of imatinib was deleted by modifying its chemical structure (see the related article beginning on page 4044). The anticancer activity of the reengineered agent, called WBZ_4, was instead preserved against gastrointestinal stromal tumors in both in vitro and in vivo models via inhibition of KIT tyrosine kinase, and the desired safety was demonstrated with less cardiotoxicity of WBZ_4 compared with imatinib via the inhibition of JNK. The study shows that structural reengineering of a kinase-inhibitory drug to improve tolerability while preserving efficacy is feasible.

1224 related Products with: Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.

Top five cancer tissue ar Oral squamous cell cancer Head & Neck cancer test t Top 4 types of cancer (co Top 4 types of cancer (co Recombinant Human Interfe Native Influenza HA (A To Native Influenza HA (A To Native Influenza HA (A To Cell Meter™ Fluorimetri Cell Meter™ Fluorimetri T-2 Toxin Mycotoxins ELIS

Related Pathways